On September 09, 2021 Ashvattha Therapeutics, a clinical stage biotech company focused on novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in neurology, neuro-oncology, and ophthalmology, reported that Jeffrey Cleland, Ph.D., Chairman, CEO and President will be presenting at the following upcoming virtual and in-person investor conferences (Press release, Ashvattha Therapeutics, SEP 9, 2021, View Source [SID1234587466]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HC Wainwright 23rd Annual Global Investment Conference, Virtual (Sept 13-15)
Cantor Fitzgerald Global Healthcare Conference, Virtual (Sept 27-30)
BioFuture, Cure by Deerfield, 345 Park Avenue South, New York, NY (Oct 5-6)
Jeffrey Cleland, Ph.D., Chairman, CEO and President will present a corporate overview focused on Ashvattha’s clinical pipeline and corporate strategy.

"We recently announced positive interim data from our ongoing Phase 2 PRANA clinical study of our lead candidate OP-101 in severe COVID-19 patients, and will give an update on our additional clinical programs," said Dr. Cleland. "OP-101 is the only clinical-stage therapeutic with the ability to shut down multiple pathways causing hyperinflammation. We look forward to speaking with investors and potential partners at these upcoming events, as we advance our novel pipeline of hydroxyl dendrimer therapeutics. Updates will include the plans for D-4517.2, a subcutaneous treatment for ocular neovascular disease, and OP-801, a novel radio-imaging agent, to be studied in combination with OP-101 in ALS patients."